Vial

FEBRUARY 15, 2024

Clinical trials play a crucial role in advancing medical breakthroughs, but effective management is essential to unlock their full potential. Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. over the forecast period (2022-2030).

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

Vial

APRIL 18, 2024

Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding. Specifically, the global ophthalmic clinical trials market, valued at USD 1.5 from 2023 to 2030. Dr. Stephen McLeod, M.D.,

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

Vial

MARCH 27, 2024

The Costs of Working with a CRO Running clinical trials is an integral part of the pharmaceutical industry, crucial to the development and approval of new drugs and treatments. However, because these trials come with a significant financial burden, sponsor companies are constantly seeking ways to optimize their operations.

Clinical Trials 52

Clinical Trials Trials International Compliance 52

DrugBank

NOVEMBER 4, 2024

The pharmaceutical industry is the primary source of antibiotic innovation; therefore, it must lead the way in combating resistance.   trillion loss in GDP by 2030 shows the urgency of this crisis.    Pharmaceutical companies are, therefore, exploring innovative approaches.

Pharmaceutical Companies 71

Pharmaceutical Companies Government Pharmaceuticals DNA 71

Codon

NOVEMBER 3, 2024

But they will need to do so if they want to meet the goals set out by the End TB Strategy , namely, to reduce TB cases by 80 percent and curb deaths by 90 percent before 2030. A 1994 review of 14 prospective trials and 12 case-control studies revealed that the BCG vaccine reduced the risk of TB by 50 percent. Subscribe to Asimov Press.

Vaccine 87

Vaccine Trials Therapies Treatment 87

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

The Pharma Data

FEBRUARY 24, 2022

with more than 8 million cases expected by 2030. “In its phase III trials, empagliflozin has shown a statistically significant and clinically meaningful benefit in patients with heart failure across the spectrum of ejection fraction,” said Javed Butler, M.D., chairman, Department of Medicine, University of Mississippi.

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

The Pharma Data

FEBRUARY 22, 2022

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030.

Science 52

Science Disease Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

MARCH 11, 2021

And at Pharmaceuticals, we are seeing success in our late-stage pipeline and are very well positioned with the investments we are making in our future. We plan to continue to grow at Pharmaceuticals despite patent expirations and only expect to register a modest decline in sales in 2024,” he said. through 2023.

Science 52

Science Pharmaceuticals Licensing Licensing 52

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. by the time Bancel made it over to Flagship, where Afeyan delivered his pitch: He wanted Bancel to work on a startup that had so far hired only a single staff scientist and conducted just one mouse trial. “It was about 6 p.m.

Engineering 84

Engineering Vaccine Production RNA 84

The Pharma Data

NOVEMBER 5, 2020

REGN-COV2 trial in the COVID-19 outpatient setting met primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. In October 2020 , the Company and Sanofi announced that a Phase 3 trial met its primary and all key secondary endpoints in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma.

Production 40

Production FDA Trials FDA Approval 40

The Pharma Data

MAY 4, 2021

.” The arrangement is part of Lilly ‘s philanthropic efforts and supports Lilly 30×30, the company’s goal to improve access to quality health care for 30 million people living in settings with limited resources, each year, by 2030. We call this global effort Lilly 30×30.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

APRIL 27, 2021

Pharmaceuticals. First-quarter 2021 Pharmaceutical sales increased 3.8% reflecting increased competition partially offset by demand growth partly related to clinical trial supply and price upside in Europe. Pharmaceuticals business operating income. First-quarter business operating income (BOI) increased 4.0%

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

JANUARY 9, 2021

This growth primarily reflects increased sales of contract development and manufacturing (CDMO) services to pharmaceutical and biotechnology innovators and government/non-government organization (NGO) customers, as well as higher product sales. In working together, we envision protecting or enhancing 1 billion lives by 2030.

Government 40

Government Vaccine Production Licensing 40

The Pharma Data

FEBRUARY 8, 2021

We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks. Pharmaceuticals. Fourth-quarter 2020 Pharmaceutical sales increased 2.4% Fourth-quarter 2020 Pharmaceutical sales increased 2.4% In 2020, Pharmaceuticals sales increased 3.1% Specialty Care.

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

FEBRUARY 4, 2021

We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks. Pharmaceuticals. Fourth-quarter 2020 Pharmaceutical sales increased 2.4% Fourth-quarter 2020 Pharmaceutical sales increased 2.4% In 2020, Pharmaceuticals sales increased 3.1% Specialty Care.

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

SEPTEMBER 15, 2020

The World Health Organization has set goals for countries to take action to eliminate cervical cancer by 2030. approval, the FDA considered data from the Roche-sponsored registrational IMPACT (IMproving Primary screening And Colposcopy Triage) trial, which enrolled approximately 35,000 women in the U.S. In 2019, Roche invested CHF 11.7

FDA Approval 52

FDA Approval FDA Laboratories Disease 52

The Pharma Data

NOVEMBER 22, 2020

About EZEPROGIND (AZP2006): Alzprotect is developing a drug candidate, EZEPROGIND, whose mode of action, acting on Progranulin secretion, is clearly different from other products developed in the past 15 years by the pharmaceutical industry. EZEPROGIND, which is kicking off phase 2a trials, is a bioavailable neurotrophic inducer.

Drugs 40

Drugs Disease Clinical Trials Licensing 40

The Pharma Data

DECEMBER 18, 2020

billion: Norway has signed a new commitment of NOK 1 billion to the International Finance Facility for Immunisation (IFFIm), to be paid from 2021 to 2030. 9 of these candidates are still in development, and 7 are in clinical trials. This funding will support the Gavi COVAX AMC and comes on top of earlier commitments of NOK 164.1

Vaccine 52

Vaccine Government International Virus 52